



## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Gastrointestinal Oncology*

**Manuscript NO:** 82027

**Title:** Lipid metabolism of hepatocellular carcinoma impacts targeted therapy and immunotherapy

**Provenance and peer review:** Invited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 06418739

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Doctor

**Reviewer's Country/Territory:** Japan

**Author's Country/Territory:** China

**Manuscript submission date:** 2022-12-04

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2022-12-05 23:03

**Reviewer performed review:** 2022-12-07 09:30

**Review time:** 1 Day and 10 Hours

|                           |   |
|---------------------------|---|
| <b>Scientific quality</b> | <input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good<br><input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish            |
| <b>Language quality</b>   | <input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing<br><input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection |
| <b>Conclusion</b>         | <input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority)<br><input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection             |
| <b>Re-review</b>          | <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No   |



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

|                                     |   |
|-------------------------------------|---|
| <b>Peer-reviewer<br/>statements</b> | Peer-Review: [ <input checked="" type="checkbox"/> ] Anonymous [ <input type="checkbox"/> ] Onymous |
|                                     | Conflicts-of-Interest: [ <input type="checkbox"/> ] Yes [ <input checked="" type="checkbox"/> ] No  |

### **SPECIFIC COMMENTS TO AUTHORS**

In the manuscript (Manuscript ID: 82027) by Xiaochen Feng and colleagues entitled “Lipid metabolism of hepatocellular carcinoma impacts targeted therapy and immunotherapy”, the authors summarized that the abnormal lipid metabolism in HCC and their prognostic impact on HCC patients. Furthermore, this manuscript reviewed the impacts of lipid metabolism on the current main drug treatment for HCC such as sorafenib, Lenvatinib, and cabozantinib. The topic is very interesting. However, the combination of atezolizumab and bevacizumab is currently the standard of care as first-line treatment for advanced HCC. The authors should discuss as much as possible the impact of aberrant lipid metabolism on atezolizumab or bevacizumab.



## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Gastrointestinal Oncology*

**Manuscript NO:** 82027

**Title:** Lipid metabolism of hepatocellular carcinoma impacts targeted therapy and immunotherapy

**Provenance and peer review:** Invited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 06467439

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Doctor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** China

**Manuscript submission date:** 2022-12-04

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2022-12-11 13:54

**Reviewer performed review:** 2022-12-21 02:52

**Review time:** 9 Days and 12 Hours

|                           |   |
|---------------------------|---|
| <b>Scientific quality</b> | <input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good<br><input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish            |
| <b>Language quality</b>   | <input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing<br><input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection |
| <b>Conclusion</b>         | <input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority)<br><input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection             |
| <b>Re-review</b>          | <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No   |



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

|                                     |   |
|-------------------------------------|---|
| <b>Peer-reviewer<br/>statements</b> | Peer-Review: [ <input checked="" type="checkbox"/> ] Anonymous [ <input type="checkbox"/> ] Onymous |
|                                     | Conflicts-of-Interest: [ <input type="checkbox"/> ] Yes [ <input checked="" type="checkbox"/> ] No  |

### **SPECIFIC COMMENTS TO AUTHORS**

The article takes a look at the specific changes in HCC metabolism reprogramming lipid metabolism in hepatocellular carcinoma (HCC) and their implications for both HCC therapeutic approaches. Therapeutic strategies for HCC targeting lipid metabolism and how they can be rationally combined with targeted therapy or immunotherapy are also described. Of some value. As the metabolic pathways are very complex, it is suggested that some of the metabolic processes could be shown in diagrams and that the specific sites of action of the relevant drugs could be labelled on the diagrams for greater clarity.



## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Gastrointestinal Oncology*

**Manuscript NO:** 82027

**Title:** Lipid metabolism of hepatocellular carcinoma impacts targeted therapy and immunotherapy

**Provenance and peer review:** Invited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 06467494

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Doctor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** China

**Manuscript submission date:** 2022-12-04

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2022-12-14 14:26

**Reviewer performed review:** 2022-12-23 16:14

**Review time:** 9 Days and 1 Hour

|                           |   |
|---------------------------|---|
| <b>Scientific quality</b> | <input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good<br><input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish            |
| <b>Language quality</b>   | <input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing<br><input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection |
| <b>Conclusion</b>         | <input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority)<br><input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection             |
| <b>Re-review</b>          | <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No   |



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

|                                     |   |
|-------------------------------------|---|
| <b>Peer-reviewer<br/>statements</b> | Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous |
|                                     | Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No  |

### **SPECIFIC COMMENTS TO AUTHORS**

Liver is the transfer station of nutrition and one of the main organs of lipid metabolism. It is of great value to elucidate the relationships between lipid metabolism and oncogenesis, progression and drug-resistance of hepatocellular carcinoma, which help to search for therapeutic targets. This manuscript summarized involvement of lipid metabolism-related molecules and signaling pathways in the occurrence and development of hepatocellular carcinoma and their impacts on tumor immune environment, and reviewed progress of researches combining lipid metabolism targeted reagents with tyrosine kinase inhibitors or immunotherapy, providing fresh light for subsequent further studies. This is one of the few reviews on lipid metabolism influencing target therapy and/or immunotherapy for hepatocellular carcinoma, and worth publishing.